Alt-Health DM Update #1 (559 megabytes) Next uploads will be under this link.
(Rest of the write-ups on this page this week 9/8/20)
Every ad on this page had an insertion in 2020 unless stated otherwise.
Marginal ads are falling by the wayside faster in late 2020.
Likely, the sharp drop in newsstand and retail point of sale of newspapers has knocked weaker products and poorer performing ads out of the market.
The STAR rating assigned to each ad reflects the number of insertions, as accurately as can be ascertained by the listed number of results in the archive.
For example, the results for Urivarx in 2020 are below. The actual number of insertions is something like ten fold what the archive shows.
Urivarx remains one of the blockbusters in its space and so it’s assigned a 4.5 out of 5
By comparison, here are the results for TruDNA during 2020.
The advertiser seems to have stopped running the ad in early March which would seem to suggest it was marginally successful and they pulled the plug 2-3weeks after the quarantine hit.
Product: AloeCure
Market: Digestion is the core and original market. Anti-aging has been the lead approach since 2019 and it’s positioned as an all-in-one super supplement.
Earliest ad insertion: April 2010
Current: Yes
Stars 5 of 5
AloeCure continues its 10-year evolution and during 2020 is now running with anti-aging first and digestion as a secondary product benefit.
If I had to guess, I’d say AC has reached its high water mark because there’s less of the voracious testing, seen just a few years ago, since they’ve drifted from digestion to anti-aging.
Scientists Target New Acid Reflux Pill for Anti-Aging Research is the winner as of September 2020
Leading Ingredient For Acid Reflux Bouts Linked To Anti-Aging Phenomenon They’ve run this one as a full page when they can get the rates.
This Amazing Acid Reflux Pill Has Really Weird Health Benefits This had a few dozen insertions between 10-19 and 02-20
Leading Acid Reflux Pill Creates Immune System Phenomenon A few dozen insertions in April, but no staying power. This seems to be the norm for many supplement sellers who’ve tried to “cross over” into immune defense.
Product: Urivarx (aka BladderMax)
Market: Incontinence. Urivarx is still killing it in print and the advertiser is sticking with their proven leads, while continuing to vigorously test. Urivarx/BladderMax is definitely on the short list for best selling supplements in print.
Earliest ad insertion: December 2016
Current: Yes
Stars 4.5 of 5
This New Bladder Control Pill May Replace Adult Diapers This one is top dog in late 2020.
Rumors of New Bladder Control Pill Have Adult Diaper Companies in a Panic Ran from October 2019 through December 2019.
Adult Diaper Companies Panic as New Bladder Pill Slashes Pad Use Also running STRONG since October 2019
Adult Diaper Companies Panic as New Bladder Pill Slashes Pad Use This one is a variation of the above which was tested several times. The insertion without the cross-out is the winner.
New Pill Strengthens The Bladder Muscles, Reducing Accidents and Bed Wetting February of 2020 to June of 2020. These guys keep pushing the envelope when it comes to testing.
New Bladder Control Pill Sales May Surpass Adult Diapers By 2021 This is a full page for BladderMax and is a revival of the “claim by date” or “claim in time frame” that was all the rage five years ago. The “BladderMax” product name looks like it’s taking the pole position over urivarx in September of 2020.
Product: Diabasens (aka Neuriterx)
Market: Neuropathy
Earliest ad insertion: May 2018
Current: Yes
Stars 4 of 5
Researchers Close in on a Pain Reliever Specific to Nephropathy This version has been running in Canada only during 2020, likely due to compliance.
Tortured by Neuropathy Discomfort? This has been doing well since May of 2019 and is picking up the rate of insertions in September of 2020. They are grabbing full pages for this hot insertion when they can get the rates. The “Neuriterx” name has largely replaced “Diabasens.”
A New Weapon For Burning, Tingling, Numb Legs and Feet This ran from May of 2019 to January 2020 and is retired in favor of: “Tortured by Neuropathy Discomfort?” They are grabbing full pages for this one when they can get the rates.
Product: Vesele
Market: Men’s health
Earliest ad insertion: May 2016
Current: Yes
Stars 3.5 of 5
Viagra’s Patent Has Finally Expired, Opening the Doors to Less Expensive Sex Pills This one is a consistent winner throughout 2020 in the men’s health market.
New Male Potency Formula Makes “The Little Blue Pill” Obsolete Several hundred insertions and was abandoned in August of 2018.
New Men’s Sex Pill Makes Viagra Obsolete Again, this and the above were the dominant leads from 2016 into 2018. The “Viagra’s patent” expiring is some potent gas in the engine of this insertion and plays on the universal recognition of Viagra.
Generic Viagras “Stiffest” Competition Yet Isn’t a Drug But a Natural Extract More proof that humor, no matter how clever, is playing against the odds in direct response. This one was a dud and had only a handful of insertions.
Product: FlexJointPlus
Market: Joint Pain
Earliest ad insertion: August 2016
Current: Yes
Stars 3.5 of 5
New Pill Could Put Florida Joint Pain Injection Companies Out Of Business Half-page insertions all over the place for this ad in September of 2020.
Washington Over-55s May Be Eligible For New $2 Joint Pain Pill They tested this one in March with several dozen insertions. Advertiser dropped it since.
Pill Used in Germany For 53 Years Relieves Joint Pain In 7 Days Without Side Effects This “origin marketing” lead is fatiguing for advertisers across the board — there’s just been too much of it for the last few years. This ran from August of 2016 to April of 2019.
New Pill Could Put Joint Pain Injection Companies Out Of Business The full-pager when they can get it in trade publications.
Product: REMfresh
Market: Sleep support
Earliest ad insertion: August 2017
Current: Yes
Stars 3.5 of 5
Finally a Breakthrough…7 Hour Sleep Support This is sold by retail as well.
Product: Prixelin
Market: Memory
Earliest ad insertion: August 2017
Current: Yes
Stars 3.5 of 5
Demand Soars in Alabama For New Pill That Reverses Memory Loss The Rod Napier inspired “Demand Soars” is all this advertiser is running with in late 2020 for this memory pill with a three year vintage.
This advertiser is a modest tester.
Amazing Pill Reverses Memory Loss Used In Italy For 31 Years Goes On Sale Nationwide They pulled the plug on this one in March of 202 after five housand insertions that ran since April 0f 2019.
Top Doctors Rush To Give Seniors. A Cutting Edge New Pill That. Reverses Mental Decline A poor performer early on in this product’s lifetime.
Product: Sinuprol (aka Primacell)
Market: Sinus
Earliest ad insertion: October 2018
Current: Yes
Stars 3 of 5
This product is inspired by the long time direct mail winner, Flora Source.
Breakthrough From #1 U.S. Hospital Clears up Sinus and Nasal Problems – Fast! Not a giant market — usually requires a longer pitch, like Nutrihealth’s direct mail packages. This ran from late 2018 through June of 2020 and is slowing down.
This Weird Herb from Egypt Surprises Doctors with its Effects on Breathing and Lungs This had a few dozen insertions in October of 2019. This “weird/strange” herb lead seems like it’s on its last legs.
Doctors Shocked by New Nasal & Sinus Pill That Works in Amazing Way A decently performing ad with a few hundred insertions throughout 2019.
Product: Audiolo-G
Market: Hearing
Earliest ad insertion: January 2020
Current: Yes
Stars 2.5 of 5
This is one small market by comparison to the products on this page. It seems like the market is not buying the core claim of this product in significant enough numbers, though not for lack of testing.
Greek Inventor’s Eardrops Could Make Hearing Aids Obsolete By 2023
Inventor Shocks Medical World with New Hearing Aid Drop A first stage product headline that didn’t take off. Insertions in January of 2020 and then dropped.
Greek Inventor Claims His “Miracle Hearing Drops” Helped an Entire Village A handful of insertions only.
Greek Inventor’s Eardrops Could Make Hearing Aids Obsolete by 2023 (Full page) If there is a control ad for this product, this is it.
Product: Veraflex
Market: Joint pain
Earliest ad insertion: October 2018
Current: Yes
Stars 3 of 5
Veraflex is one of those insertions that showed up in the thinning USA Today most weekdays for months during 2020.
Good News for Americans, Bad News for Pain Drugs A solid control since October of 2018. The advertiser rarely tests anything against its top performer.
US Surgeon Generals report reveals the shocking truth about joint pain A few dozen insertions of this in May and early June of 2020 and no more.
Product: Trexar
Market: Neuropathy
Earliest ad insertion: May 2020
Current: Yes
Stars 3 of 5
Doctors Dead Wrong About Leg and Foot Discomfort Seems to be a newcomer, yet has plenty of insertions since May
A Major Discovery for Neuropathy Discomfort: The TRPA1 Channel Too cerebral of a headline? Just a handful of insertions.
Product: H2Go
Market: Digestion
Earliest ad insertion: May 2015
Current: No
Stars 3 of 5
How to Beat Constipation Naturally
Seems like this one is finally on life support after marginal success over the last five years. Last insertion I can find was in May of 2020,